ACXP — Acurx Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1736243 ·
Last close
$1.25
Market Cap
$5.37M
52W High
$8.14
52W Low
$1.23
ADV30
87,229
Next earnings
2026-11-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -2,307,228 | -2,254,173 | 10,984,777 | 10,656,386 | 2,832,746 |
| Mar 2026 | 0 | — | -1,715,990 | -1,680,982 | 9,539,952 | 9,254,813 | 2,526,809 |
| Dec 2025 | 0 | — | -1,617,116 | -1,578,276 | 7,689,535 | 7,556,100 | 2,420,943 |
| Sep 2025 | 0 | — | -2,028,701 | -1,992,790 | 6,105,211 | 5,906,802 | 2,468,175 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-6,143,816
Investing CF
—
Financing CF
$10,754,742
CapEx
—
Dividends Paid
—
Buybacks
$0
EPS Diluted TTM
$-5.89
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-76,969,476
Inventory
—
Receivables
$56,313
ST Investments
—
EBIT TTM
$-7,631,490
Pretax Income TTM
$-7,498,327
Interest Exp TTM
—
Analysts
3
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -8,091,983 | -7,966,538 | 7,689,535 | 2,420,943 | 5,268,592 | -6,787,782 |
| Dec 2024 | 0 | -14,123,227 | -14,103,103 | 3,857,963 | 3,242,842 | 615,121 | -10,383,431 |
| Dec 2023 | 0 | -14,577,768 | -14,577,768 | 7,709,123 | 3,042,438 | 4,666,685 | -9,800,885 |
| Dec 2022 | 0 | -12,092,776 | -12,092,776 | 9,376,706 | 2,061,685 | 7,315,021 | -7,542,290 |
TTM Snapshot
Revenues TTM
$160,453
NetIncome TTM
$-7,498,327
OpCashFlow TTM
—
Assets (Latest)
$9,539,952
Forward EPS
$-1.75
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DRMA | Dermata Therapeutics, Inc. | $5.30M | $1.07 | — |
| PULM | Pulmatrix, Inc. | $5.58M | $1.53 | — |
| LNAI | Lunai Bioworks Inc. | $5.08M | $1.12 | — |
| KALA | KALA BIO, Inc. | $5.74M | $0.30 | — |
| XBIO | Xenetic Biosciences, Inc. | $4.97M | $2.12 | — |
News headlines (Yahoo Finance, 1h cache)
Acurx Pharmaceuticals Takes Its Antibiotics Story Global Through a 12-Month Series with New to The Street
2026-10-05 17:25 · Yahoo
Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection
2026-09-29 12:01 · Yahoo
New to The Street Broadcasts Tonight at 6:30 PM ET Across the United States, Latin America and MENA, Featuring BioVie, Acurx Pharmaceuticals, Lantern Pharma and SafeSpace Global
2026-09-19 15:45 · Yahoo
Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomi
2026-09-14 12:01 · Yahoo
Acurx Pharmaceuticals Inc (ACXP) (Q2 2026) Earnings Call Highlights: FDA Signals Potential ...
2026-08-21 01:02 · Yahoo
Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update
2026-08-14 11:01 · Yahoo
Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics
2026-08-12 12:01 · Yahoo
Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection
2026-07-14 12:00 · Yahoo
Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update
2026-07-08 12:00 · Yahoo
Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Developmen
2026-06-16 12:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.